Desert Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 14-12-2024
- Paid Up Capital ₹ 1.90 M
as on 14-12-2024
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Profit 1.21%
(FY 2020)
- Ebitda
- Net Worth -0.02%
(FY 2020)
- Total Assets 0.02%
(FY 2020)
About Desert Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.90 M, as per Ministry of Corporate Affairs (MCA) records.
Murlidhar Agrawal and Nitin Agrawal serve as directors at the Company.
- CIN/LLPIN
U24100MH2009PTC190697
- Company No.
190697
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Desert Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murlidhar Agrawal  | Director | 02-May-2013 | Current |
| Nitin Agrawal | Director | 02-May-2013 | Current |
Financial Performance and Corporate Structure Insights of Desert Pharma.
Desert Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 1.21% increase in profit. The company's net worth dipped by a decrease of 0.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Desert Pharma?
In 2020, Desert Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vsr Steel Fabricators Private LimitedActive 26 years 8 monthsMurlidhar Agrawal and Nitin Agrawal are mutual person
- Mittal Infraventures Private LimitedActive 16 years 11 months
Murlidhar Agrawal and Nitin Agrawal are mutual person
- Priority Exports Private LimitedActive 17 years 2 months
Murlidhar Agrawal and Nitin Agrawal are mutual person
- Nupur Hire Purchase And Finance Company Private LimitedActive 26 years 1 month
Murlidhar Agrawal and Nitin Agrawal are mutual person
- Murlidhar Charitable FoundationActive 2 years 9 days
Murlidhar Agrawal and Nitin Agrawal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Desert Pharma?
Unlock and access historical data on people associated with Desert Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Desert Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Desert Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
